Imaging Findings of Vigabatrin-Associated Neurotoxicity in a 12-Month-Old With Infantile Epileptic Spasm Syndrome
- PMID: 40861777
- PMCID: PMC12372853
- DOI: 10.7759/cureus.88593
Imaging Findings of Vigabatrin-Associated Neurotoxicity in a 12-Month-Old With Infantile Epileptic Spasm Syndrome
Abstract
Infantile epileptic spasm syndrome (IESS), also known as West syndrome, is a rare and severe form of epileptic encephalopathy of infancy. Vigabatrin, a selective, irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), is currently the only FDA-approved medication for the management of IESS. Known associations include neurotoxicity and visual defects. A 12-month-old female with a history of developmental delay and IESS, currently being treated with vigabatrin, was evaluated with magnetic resonance imaging (MRI) after presenting with excessive drowsiness and poor feeding. Imaging findings were significant for new areas of restricted diffusion involving the anterior commissure, medial aspect of the globi pallidi, and the medial thalami bilaterally compared to the patient's MRI prior to starting vigabatrin. These findings suggested vigabatrin neurotoxicity. This case demonstrates the clear relationship between vigabatrin use and the development of stereotypical imaging abnormalities associated with neurotoxicity. It also further illustrates the importance of early recognition and withdrawal of therapy in order to prevent potential long-term side effects.
Keywords: anterior commissure; globi pallidi; infantile epileptic spasm syndrome; medial thalami; mri; neuroradiology; neurotoxicity; restricted diffusion; vigabatrin; west syndrome.
Copyright © 2025, Nedimyer Horner et al.
Conflict of interest statement
Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures
References
-
- Epilepsy facts and stats. [ Mar; 2025 ]. 2024. https://www.cdc.gov/epilepsy/data-research/facts-stats/index.html https://www.cdc.gov/epilepsy/data-research/facts-stats/index.html
-
- Vigabatrin (Sabril), a gamma-aminobutyric acid transaminase inhibitor for the treatment of two catastrophic seizure disorders. Cruz MP. https://pmc.ncbi.nlm.nih.gov/articles/PMC2816152/ P T. 2010;35:20–23.
-
- Smith MS, Matthews R, Rajnik M, Mukherji P. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2025. Infantile epileptic spasms syndrome (West syndrome) . - PubMed
-
- West syndrome: a comprehensive review. [ Mar; 2025 ];Pavone P, Polizzi A, Marino SD, Corsello G, Falsaperla R, Marino S, Ruggieri M. https://link.springer.com/article/10.1007/s10072-020-04600-5. Neurol Sci. 2020 41:3547–3562. - PMC - PubMed
-
- Safety and efficacy of vigabatrin for the treatment of infantile spasms. Faulkner MA, Tolman JA. https://pmc.ncbi.nlm.nih.gov/articles/PMC3663614/ J Cent Nerv Syst Dis. 2011;3:199–207. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous